NCT01093183 2023-09-13
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
University of Nebraska
Phase 1/2 Terminated
Clinical Trials
13 trialsNCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT00460031 2020-07-24
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01373294 2019-08-06
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01342172 2019-04-23
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT00348595 2019-04-12
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00403169 2017-04-20
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00933426 2016-10-26
Lenalidomide and Paclitaxel in Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01378091 2016-05-09
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Columbia University
Phase 1 Completed
NCT00654186 2014-03-28
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Oncology Specialists, S.C.
Phase 2 Completed
NCT00939510 2013-01-31
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00096525 2013-01-17
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed